Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13D Filing: Versant Venture Capital IV, L.P. and Crispr Therapeutics AG (CRSP)

Published on September 18, 2017 at 12:06 pm by Insider Monkey Staff in Hedge Funds

Page 3 of 18

Page 3 of 18 – SEC Filing

CUSIP No. 71723F103						13D

	1.	Name of Reporting Persons Versant Side Fund IV, L.P.

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)			o
		(b)			x(1)

	3.	SEC Use Only

	4.	Source of Funds (See Instructions) WC

	5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) o

	6.	Citizenship or Place of Organization Delaware, United States

Number of Shares Beneficially Owned by Each Reporting Person With			7.	Sole Voting Power 16,224 shares of common stock (2)

			8.	Shared Voting Power 0

			9.	Sole Dispositive Power 16,224 shares of common stock (2)

			10.	Shared Dispositive Power 0

	11.	Aggregate Amount Beneficially Owned by Each Reporting Person 16,224 shares of common stock (2)

	12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o

	13.	Percent of Class Represented by Amount in Row 11 0.04% (3)

	14.	Type of Reporting Person (See Instructions) PN

(1) This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) The shares are held by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. Atwood, Colella, Jaffe, Link, Robertson, Bolzon, Warden, Nielsen, Woiwode and Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VSF IV; however, they each disclaim beneficial ownership of the shares held by VSF IV except to the extent of their pecuniary interests therein.

(3) This calculation is based upon 40,591,669 Common Shares outstanding as of August 7, 2017, as reported in the Issuers 10-Q filed with the SEC on August 10, 2017.

3

Follow Crispr Therapeutics Ag (NASDAQ:CRSP)

Follow Crispr Therapeutics Ag (NASDAQ:CRSP)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 3 of 18

NASDAQ:CRSP SEC 13D Filing Crispr Therapeutics AG (CRSP)Versant Venture Capital Iv, L.p.